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Exercise Capacity, Lung Function, and Quality of Life After
Interventional Bronchoscopy
P. Leland Oviatt, MD,* David R. Stather, MD,* Gae¨tane Michaud, MD,† Paul MacEachern, MD,*
and Alain Tremblay, MDCM*
Introduction:Malignant airway obstruction accounts for significant
morbidity and mortality in patients with lung and metastatic cancer.
We prospectively assessed the effects of bronchoscopic interven-
tions for the treatment of malignant airway obstruction, with specific
attention to exercise capacity and quality of life (QoL).
Methods: This is a prospective cohort study. Patients with high-
grade, symptomatic central malignant airway obstruction were as-
sessed at baseline and then at days 30, 90, and 180 after broncho-
scopic intervention with spirometry, 6-minute walk test (6MWT),
and QoL and dyspnea questionnaires (European Organization for
Research and Treatment of Cancer Quality of Life [C30] and Lung
Cancer [LC-13] modules).
Results: Thirty-seven patients were included in the final statistical
analysis. Increases in 6MWT distance by 99.7 m (95% CI 33.2–
166.2 m, p  0.002), FEV1 by 448 ml (95% CI 203–692 ml, p 
0.001), and FVC by 416 ml (95% CI 130–702 ml, p  0.003) were
seen at day 30 compared with baseline. Clinically and statistically
significant improvements were noted in composite dyspnea scores at
day 30 by both QoL C30 (decrease of 39.9, 95% CI 21.4–58.4, p 
0.001) and LC-13 (decrease of 28.2, 95% CI 12.9–43.5, p  0.001)
questionnaires.
Conclusions: Bronchoscopic intervention for malignant airway ob-
struction is associated with improvement in 6MWT, spirometry, and
dyspnea at 30 days.
Key Words: Dyspnea, Bronchoscopy, Lung cancer, Quality of life,
Pulmonary function testing.
(J Thorac Oncol. 2011;6: 38–42)
Estimates of the incidence of central airway obstructionapproach 30% in lung cancer,1,2 with locoregional effects
that may include postobstructive pneumonia, hemoptysis,
atelectasis, dyspnea, and respiratory failure. Other tumors can
also lead to airway compromise by direct extension or via
metastasis to the airway or surrounding lymph nodes.3
Interventional bronchoscopy techniques have emerged
in the recent years as viable palliative options in the treatment
of malignant central airway obstruction. Although the tech-
nical success of such procedures has been well documented,
as have short-term improvements in performance status, spi-
rometry, and dyspnea scores, little is known regarding their
impact on overall quality of life, objective measurements of
functional status, and symptoms beyond the immediate post-
procedure period. In addition, most studies have focused on
specific interventions such as stenting, laser, or cryotherapy
as opposed to an overall approach to endoscopic treatment
that may often include more than one modality.
This study was designed to prospectively determine
the impact of a multimodality interventional bronchoscopy
approach on an objective measurement of functional sta-
tus, quality of life, dyspnea, and lung function in patients
with malignant airway obstruction 1, 3, and 6 months
postprocedure.
PATIENTS AND METHODS
Study Design
A prospective cohort study design was used to evaluate
the impact of interventional bronchoscopic techniques on
patients with malignant obstruction of the central airways.
The study was approved by the Conjoint Health Research
Ethics Board of the University of Calgary.
Subjects
Subjects aged 18 years or older with malignant airway
obstruction associated with one of the following were deemed
eligible for the study: symptomatic obstruction; obstruction
associated with more than 50% luminal narrowing of trachea
or mainstem bronchus; or obstruction causing lower lobe or
greater atelectasis. A known proven malignancy or a high
suspicion of malignancy on clinical grounds was also re-
quired for study eligibility.
Subjects with a life expectancy of less than 3 months;
those who refused consent; had a contraindication to bron-
choscopy or anesthesia; or presented with surgically resect-
able lung cancer were excluded.
Patients were screened for inclusion into the study on
referral to the Interventional Pulmonary Medicine Service at
Foothills Medical Center, an academic tertiary care center.
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Intervention
Patients received bronchoscopic treatment for malig-
nant airway obstruction as per our standard clinical approach.
Treatment modalities used in our center include mechanical
debulking and dilatation with the rigid bronchoscope (Karl
Storz Endoscopy Canada, Mississauga, ON; Bryan Corpora-
tion, Woburn, MA), endobronchial electrocoagulation and
argon plasma coagulation (ERBOTOM ICC 350, Erbe USA,
Marietta, GA), balloon bronchoplasty (CRE™ Wireguided
Balloon Dilators, Boston Scientific, Natick, MA), and airway
stenting (Ultraflex and Dynamic Y stents, Boston Scientific;
Aero stent, Alveolus, Charlotte, NC; Tracheobronxane stent,
Novatech, La Ciotat, France; Hood silicone stents, Hood
Laboratories, Pembroke, MA). Brachytherapy, photodynamic
therapy, and Nd:YAG laser treatments are not performed in
our center.
Procedures were performed in the operating room via
rigid bronchoscopy, general anesthesia, and jet ventilation. In
general, extrinsic obstructions were treated with dilatation
(via rigid bronchoscope or balloon bronchoplasty) and airway
stenting (favoring removable devices if good response to
oncological treatment/long-term survival was expected). In-
trinsic obstructions were debulked with the rigid broncho-
scope after electrocoagulation of the lesion, and stenting was
considered in cases of recurrent disease or if additional
oncologic treatment options were limited. Finally, mixed
obstructions were treated with a combination of electrocoag-
ulation and rigid bronchoscopic debulking followed by stent
placement.
Patients received further chemotherapy, radiation ther-
apy, or other treatments as recommended by their oncologist.
Outcome Measurements
Basic demographics including the subject age, gender,
tumor cell type, and cancer stage were collected at baseline.
Information on the location of obstruction, degree of airway
patency before and after bronchoscopic intervention, and
procedure-related complications were recorded, along with
the specific bronchoscopic modalities used.
The primary outcome measure for this study was the
change in 6-minute walk test (6MWT) from baseline. Sec-
ondary outcome measures included overall quality of life
(QoL) as well as overall and dyspnea-specific symptom
scales from the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) and lung cancer module (LC13); spirometry;
pulse oximetry; resting MRC dyspnea score; modified Borg
dyspnea score; and Borg dyspnea score at completion of
6MWT. Patients were evaluated at baseline and at days 30,
90, and 180. In addition to the above outcomes, airway-
related complications were assessed at each visit, as well as
any other oncologic treatment received. Flexible bronchos-
copy was planned for all patients at 30 days after rigid
bronchoscopy for endobronchial evaluation of the airway
patency and assessment of interval disease progression or
other complications.
Statistical Analysis
Sample size calculations based on the differences in
6MWT could not be determined as the variability of change
in the walk test was not known in this patient population. This
study also had an important descriptive component that was
thought to be more important than the results of the 6-minute
walk tests alone. Nevertheless, a sample size of 40 was
selected and estimated to allow the detection of a 30 m
change in 6MWT, assuming a SD of 65 m around the change
( 0.05,  0.8).
Repeated measures analysis via a linear mixed models
method and estimated margin of means was used to compare
overall differences in outcomes between day 0, 30, 90, and
180. When overall significance was noted (p  0.05), paired
t tests were completed, using Bonferroni correction (p 
0.05/3), to contrast day 0 versus day 30, day 0 versus day 90,
and day 0 versus day 180. All data were analyzed with the use
of the SPSS software package (Version 16.0; SPSS Inc.,
Chicago, IL).
RESULTS
Forty subjects were initially recruited to participate in
the study, with three excluded after enrolment because they
failed to meet study criteria. The results of remaining 37 were
analyzed. Figure 1 demonstrates the number of participants
alive and having completed follow-up assessments at each
scheduled time point. Mortality data were available for 36 of
the 37 patients, with one patient without mortality data
withdrawing from the trial after day 30 time point. Median
survival for the cohort was 166 days (23.7 weeks), and
6-month survival was 46%.
Cohort demographics, tumor cell types, location, and
type of obstruction in addition to history of thoracic radiation
treatment and details of bronchoscopic interventions are de-
tailed in Table 1. The majority of subjects had a diagnosis of
non-small cell lung carcinoma (NSCLC); and obstruction
involved large central airways (bronchus intermedius or
larger) in 89% of cases. All obstructions were graded at
greater than 50% luminal occlusion, with the majority (80%)
being graded as between 75 and 100%.
After the bronchoscopic procedure, 34 of the 37 sub-
jects (91.9%) had successful reestablishment of patency,
which is defined as restoration of obstructed airway lumen to
less than 50% obstruction.
Results of the primary and secondary outcome mea-
sures at baseline and at days 30, 90, and 180 of follow-up are
summarized in Table 2. With regard to the primary outcome
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FIGURE 1. Cohort survival and available data for all time
points (baseline N  37).
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measure of 6MWT, statistically significant changes where
noted with improvements of 99.7, 123.6, and 122.3 m from
baseline at days 30, 90, and 180, respectively. At day 30, 32%
of patients demonstrated an improvement in 6MWT of
greater than 50 m. Statistically significant improvements at
day 30 were also noted in the dyspnea scores from QLQ-
C30 and LC-13 scales, resting Borg scale, FEV1, and FVC
but not for overall QoL score, exercise Borg, and MRC
dyspnea scales. At day 30, 48.6% (18/37), 45.9% (17/37),
and 43% (16/37) of patients demonstrated an improvement
of 5 points or greater in QLQ-C30 dyspnea score, LC-13
dyspnea score, and overall QoL score, respectively. Of the
19 patients who underwent repeat flexible bronchoscopic
evaluation 30 days after initial intervention, 16 (84%)
maintained airway patency.
Subgroup analysis of patients who received prior radi-
ation therapy, postprocedural radiation therapy, stage III
versus stage IV non-small cell lung cancer, or those with
primary lung malignancy versus metastatic disease failed to
reveal statistically significant effects on any of the outcome
measures. Adverse events relating to the procedure are de-
scribed in Table 3. Notable adverse outcomes included de-
velopment of bilateral vocal cord paralysis (in a patient with
preexisting right cord paralysis due to invasive thyroid car-
cinoma) requiring tracheostomy and asphyxiation death of
one patient secondary to occlusion of a silicone stent with
tenacious secretions at day 30 postprocedure. One stent
migration requiring removal the day after placement occurred
while another patient also underwent removal of an airway
stent between the day 30 and 90 visits because of fungal
colonization and persistent secretions.
DISCUSSION
This study demonstrates the positive impact of inter-
ventional bronchoscopic procedures in patients with central
malignant airway obstruction. Specifically, clinically and
statistically significant improvements in 6MWT distance (our
primary outcome measure) as well as in spirometry, dyspnea-
specific QoL scores, and overall QoL were noted.
The 6MWT is a commonly used objective method to
assess the functional status of patients with lung disease,
including lung cancer,4 and can be used to measure the
response to medical interventions in patients with moderate to
severe lung disease.5 The 99.7 m mean improvement noted at
the 30-day evaluation in our cohort is above the minimal
clinically important difference for this test of 54 to 80 m.6 In
addition, these results compare favorably with other interven-
tions in cancer patients. Evaluation of the effect of chemo-
therapy for NSCLC on 6MWT distance in a recent trial
suggests that it has a tendency to remain unchanged in the
majority and declined in the minority of patients, thereby
reducing the group mean.4 Although we are not aware of
studies assessing the effect of radiotherapy on 6MWT, we did
not detect any differences in patients who did or did not
receive additional radiation treatments after bronchoscopy.
These findings and the rapid (30 day) improvements noted
suggest that the bronchoscopic treatments and not the addi-
tional oncologic therapy received by study subjects were
responsible for the improvement.
While many reports have suggested subjective im-
provements in dyspnea after interventional bronchoscopy,
our data confirm this improvement using objective, validated
quality of life questionnaires. The improvements noted, with
decreases in dyspnea scores of 28 (LC13) and 40 (C30) on
100-point scales at day 30, correlate with “moderate” to “very
much” in terms of patient-perceived degree of improvement,
with a change of 5 considered the minimal clinically impor-
TABLE 1. Patient Characteristics, Description of Airway
Lesions, and Treatment Modalities (N  37)
Patient Characteristics n (%)
Mean age (yr) 62.9 (range, 25–80)
Female 21 (56.8%)
Male 16 (43.2%)
Tumour type
Primary NSCLC 24 (64.9%)
Stage III 12 (32.4%)
Stage IV 12 (32.4%)
Primary small cell lung cancer 1 (2.7%)
Breast cancer 3 (8.1%)
Colon cancer 4 (10.8%)
Esophageal cancer 3 (8.1%)
Thyroid cancer 1 (2.7%)
Metastatic osteosarcoma 1 (2.7%)
Location of obstruction (percent of patients
with obstruction)
Trachea 12 (32.4%)
Right mainstem 16 (43.2%)
Left mainstem 11 (29.7%)
Bronchus intermedius 8 (21.6%)
Right lower lobe 3 (8.1%)
Left lower lobe 1 (2.7%)
Type of obstruction (percentage of all
obstructions)
Extrinsic 18 (35.3%)
Intrinsic 7 (13.7%)
Mixed 26 (51.0%)
Thoracic radiation therapy
Prior history of radiation treatment 9 (24.3%)
Post-bronchoscopy radiation treatment 22 (59.5%)
Bronchoscopic modality utilized (1 modality/
subject is possible, % is
proportion of cohort receiving
modality)
Electrocautery
Electrocautery probe (soft coagulation) 19 (51.4%)
Argon plasma coagulation 3 (8.1%)
Electrocautery forceps 2 (5.4%)
Electrocautery snare 1 (2.7%)
Balloon bronchoplasty 12 (32.4%)
Airway stent
Uncovered metal self-expandable 11 (29.7%)
Covered metal self-expandable 6 (16.2%)
Silicone (strait) 2 (5.4%)
Silicone (Y-stent) 7 (18.9%)
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tant difference.7 These improvements are somewhat larger
than seen in another recent study using the same measure-
ment tools, which appears to relate to a higher degree of
symptomatology at baseline in this study cohort.8
Several authors have investigated the impact of pallia-
tive chest radiation treatment in patients with advanced lung
cancer, but this information is not available specifically for a
patient population such as ours with central airway obstruc-
tion. In general, while approximately one-third of patients
experience improvement in dyspnea after chest radiation,9
overall mean dyspnea scores seem to change little with
treatment.10–12 The results do appear better when radical
radiation doses are administered.13 It has been demonstrated
that the addition of brachytherapy to external beam radiation
therapy leads to improved mean dyspnea score, especially in
a subgroup of patients with obstructive tumors, and patients
with atelectasis were more likely to experience radiologic
re-expansion (57 versus 35%), suggesting that endobronchial
therapies beyond external beam radiation are beneficial in this
patient population.10
In life-threatening situations, the administration of ra-
diation alone may be problematic as effects are delayed, and
there is potential for initial worsening of the obstruction
secondary to tissue edema. In addition, it may be technically
difficult to appropriately treat a restless patient in moderate
to severe respiratory distress who cannot lie flat or is on
life support. It is also known that in the case of an
atelectatic lung, the longer it is present, the less likely it is
to resolve with treatment.14 The role of radiation treatment
may also be limited in those previously treated or in those
with relatively radio-resistant tumors such as melanoma,
renal, and colon cancer.
Improvement in overall QoL scores over the course of
the study was also noted in our patients, although this did not
reach statistical significance at day 30. The improvement
cannot be solely attributed to the bronchoscopic treatment as
patients received standard supportive care and oncologic
treatment. Nevertheless, most studies of chemotherapy15,16 or
palliative radiation therapy10,11 in advanced NSCLC demon-
strate stabilization or delayed decline in QoL over time, as
opposed to the improvements noted in our study, again
suggesting that the bronchoscopic treatments played an im-
portant role.
The improvements seen in spirometry concur with
previous reports of interventional bronchoscopic tech-
niques.17,18 While this offers a functional rationale for the
improvement in symptoms and functional status, the effect of
interventional bronchoscopic techniques may extend beyond
simply improving lung function. Improvement in functional
status may allow for more aggressive oncologic treatment in
patients initially ineligible, including curative resection in
some cases.19,20 Avoidance of additional complications re-
sulting from airway obstruction such as hemoptysis and
postobstructive pneumonia may offer additional benefit.
Despite these benefits, it is important to reflect on the
significant short-term mortality with median survival just less
than 6 months in our cohort, despite attempts at selecting
patients with expected survival more than 90 days. While this
is in keeping with other reports, it highlights the difficulty in
determining prognosis in individual patients21 and the impor-
tance of careful discussion between the medical team and
patients relating to goals of care, preferences, and expecta-
tions before proceeding to an invasive palliative procedure.
Patients should also be aware that minor complications are
TABLE 2. Outcome Measures at Baseline and at Days 30, 90, and 180
Measure
Day 0, Mean
(SD)
Day 30 Mean, Change
(95% CI)
Day 90 Mean, Change
(95% CI)
Day 180 Mean, Change
(95% CI)
6MWT (m)* 195.7 (161.2) 295.4, 99.7 (33.2–166.2)† 319.2, 123.6 (44.0–203.1)† 318.0, 122.3 (47.8–196.8)†
EORTC QLQ-C30* 33.3 (23.6) 42.5, 9.2 (5.7 to 24.1) 52.6, 19.3 (6.9–31.6)† 55.0, 21.7 (4.5–38.9)†
C30 Dyspnea scale* 84.3 (21.8) 44.3, 39.9 (58.4 to 21.4)† 36.0, 48.3 (73.2 to 23.4)† 49.9, 34.4 (56.5 to 12.3)†
LC13 Dyspnea scale* 61.3 (22.0) 33.1, 28.2 (43.5 to 12.9)† 32.0, 29.3 (44.9 to 13.6)† 35.6, 25.7 (41.2 to 10.3)†
FEV1 (litres)* 1.283 (0.450) 1.731, 0.448 (0.203–0.692)† 1.888, 0.605 (0.339–0.870)† 1.752, 0.469 (0.214–0.724)†
FVC (litres)* 2.20 (0.785) 2.618, 0.416 (0.130–0.702)† 2.802, 0.600 (0.273–0.928)† 2.548, 0.346 (0.014–0.678)†
MRC Dyspnea* 3.88 (1.00) 3.17, 0.709 (1.436 to 0.018) 2.71, 1.17 (1.83 to 0.51)† 2.80, 1.08 (1.86 to 0.30)†
Resting Borg* 2.13 (2.32) 0.82, 1.32 (2.41 to 0.23)† 0.89, 1.24 (2.19 to 0.30)† 0.42, 1.71 (2.57 to 0.86)†
6MWT Borg* 3.92 (1.92) 2.58, 1.34 (2.61 to 0.06) 2.22, 1.70 (2.86 to 0.55)† 2.85, 1.07 (2.41 to 0.26)†
Higher scores for European Organization for Research and Treatment of Cancer (EORTC) main module (QLQ-C30) equate to improved quality of life, while higher scores for
dyspnea (C30 and lung cancer module LC13) equate to increased (worsened) symptoms.
*p  0.05 overall.
†p  0.05 compared with day 0.
NS, non-statistically significant.
TABLE 3. Procedure-Related Complications
Complication
Number of Cases
(% of Cohort)
Oropharyngeal minor trauma 3 (8.1)
Laryngospasm/upper airways swelling requiring
brief reintubation (12 h)
2 (5.4)
Intraoperative atrial fibrillation 1 (2.7)
Bilateral vocal cord paralysis 1 (2.7)
Pneumothorax 1 (2.7)
Stent migration 1 (2.7)
Significant stent occlusion by secretions (fatal in
one patient with silicone tracheal stent,
necessitated stent removal in another)
2 (5.4)
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frequent, and more severe complications including mortality
can occur in relation to these procedures.
The main limitation of this study is the attrition of our
cohort with time, because of both early mortality and loss to
follow-up. While early mortality is simply a function of the
natural history of cancer in such patients, our statistical
modeling allowed us to include all patients into the analysis
in an attempt to avoid a healthy survivor effect. In addition,
given the observational nature of our study without a control
group that did not undergo bronchoscopic intervention, a
specific causal relationship between treatment and the im-
proved outcome noted cannot be confirmed. Nevertheless, it
did not appear that additional treatments influenced results in
a subgroup analysis, and changes noted differed from those
reported with chemotherapy or radiation therapy for lung
cancer, suggesting that the bronchoscopic intervention led to
the noted improvements. Finally, we limited enrolment to
patients with relatively central lesions, with only 10% of
subjects with lobar obstructions. As such, our results may not
apply to the treatment of more distal obstructions.
The most recent ACCP Lung Cancer Guidelines make
mention of several invasive approaches to palliation of dys-
pnea commonly used during interventional bronchoscopic
procedures and recommend that malignant airway obstruction
be considered in the differential diagnosis of dyspnea.22 Our
data objectively confirm the considerable benefit of interven-
tional bronchoscopic procedures in patients with malignant
airway obstruction and suggest that these techniques be
considered as essential components of any multidisciplinary
cancer care program.
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